Trial record 1 of 1 for:
04535609
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients (STRIDE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04535609 |
|
Recruitment Status :
Completed
First Posted : September 2, 2020
Results First Posted : April 3, 2024
Last Update Posted : May 8, 2024
|
Sponsor:
Reneo Pharma Ltd
Information provided by (Responsible Party):
Reneo Pharma Ltd
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Primary Mitochondrial Myopathy | Drug: Mavodelpar Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 213 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy |
| Actual Study Start Date : | May 21, 2021 |
| Actual Primary Completion Date : | September 12, 2023 |
| Actual Study Completion Date : | October 5, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Muscle Disorders
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Mavodelpar
Once daily
|
Drug: Mavodelpar
Once daily
Other Name: REN001 |
|
Placebo Comparator: Matched placebo
Once daily
|
Drug: Placebo
Once daily |
Primary Outcome Measures :
- Change in Distance Walked During a 12 Minute Walk Test [ Time Frame: Baseline to Week 24 ]Distance walked in meters
Secondary Outcome Measures :
- Change in PROMIS Short Form - Fatigue 13a (FACIT-fatigue) Scores [ Time Frame: Baseline to Week 24 ]The PROMIS is a 13-item questionnaire to describe fatigue and its impact upon daily activities and function. Each item is scored between 1=Not At All and 5=Very Much
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects age 18 years or older with PMM as defined by the International Workshop: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adult (Mancuso et al 2017).
- A confirmed PMM diagnosis due to known pathogenic gene mutation or deletion of the mitochondrial genome. The Sponsor may authorize local genetic testing at Screening, if required, but results must be available prior to randomization of the subject.
- Documented PMM primarily characterized by exercise intolerance or active muscle pain.
- Subjects must be ambulatory and able to perform the walking tests independently (walking aids are allowed).
- Have no changes to any therapeutic exercise regimen within 30 days prior to Day 1 and be willing to remain on the same therapeutic exercise regimen for the duration of the study.
- Females should be either of non-child-bearing potential or must agree to use highly effective methods of contraception from Screening through to 30 days after last dose in the study. Males with partners who are WOCBP must also use contraception.
- Concomitant medications (including supplements) must be stable for at least 1 month prior to enrolment and throughout participation in the study.
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
Exclusion:
- Participation in a prior REN001 (previously known as HPP-593) study.
- Currently taking or anticipated to need a PPAR agonist during the study.
- Subjects with bone deformities or motor abnormalities other than related to the mitochondrial myopathy that may interfere with the outcome measures.
- Clinically significant kidney disease or impairment calculated as eGFR Grade 2 or above <60ml/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation at Screening.
- Clinically significant liver disease or impairment of AST or ALT Grade 2 or above (>2.5 x ULN), or Total bilirubin > 1.6 x ULN or >ULN with other signs and symptoms of hepatotoxicity at Screening.
- Subjects with uncontrolled diabetes and/or a Screening HbA1c of ≥11%.
- Evidence of significant concomitant clinical disease that may need a change in management during the study or could interfere with the conduct or safety of this study. (Stable well-controlled chronic conditions such hypercholesterolemia, gastroesophageal reflux, or depression under control with medication (other than tricyclic antidepressants), are acceptable provided the symptoms and medications would not be predicted to compromise safety or interfere with the tests and interpretations of this study.)
- Subjects with a history of cancer. A history of in situ basal cell carcinoma in the skin is allowed.
- Clinically significant cardiac disease and/or clinically significant ECG abnormalities such as 2nd degree heart block, symptomatic tachyarrhythmia or unstable arrythmia (right bundle branch block, left fascicular block and long PR interval are not excluded) that in the opinion of the Investigator should exclude the subject from completing exercise tests.
- Evidence of hospitalization for rhabdomyolysis within the year prior to enrolment.
- Pregnant or nursing females.
- History of sensitivity to PPAR agonists.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04535609
Locations
Show 41 study locations
Sponsors and Collaborators
Reneo Pharma Ltd
Investigators
| Principal Investigator: | Amel Karaa, MD | Massachusetts General Hospital (MGH) |
Study Documents (Full-Text)
Documents provided by Reneo Pharma Ltd:
Documents provided by Reneo Pharma Ltd:
Study Protocol [PDF] June 24, 2022
Statistical Analysis Plan [PDF] November 16, 2023
| Responsible Party: | Reneo Pharma Ltd |
| ClinicalTrials.gov Identifier: | NCT04535609 |
| Other Study ID Numbers: |
REN001-201 |
| First Posted: | September 2, 2020 Key Record Dates |
| Results First Posted: | April 3, 2024 |
| Last Update Posted: | May 8, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Muscular Diseases Mitochondrial Myopathies Musculoskeletal Diseases Neuromuscular Diseases |
Nervous System Diseases Mitochondrial Diseases Metabolic Diseases |